Ybrain's Electronic Headache Drug 'Dupang' Receives FDA Approval
Electronic medicine platform company Ybrain announced on the 20th that its migraine electronic medicine Dupang has obtained 510k approval from the U.S. Food and Drug Administration (FDA). The 510k is a system in which the FDA verifies and approves the safety and effectiveness of medical devices. It had previously received approval from the Ministry of Food and Drug Safety in Korea in 2020.
Dupang works by delivering transcutaneous electrical nerve stimulation (TENS) to the trigeminal nerve area on the forehead that causes migraines, calming the overactive nerves to relieve migraines.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "I'll Stop by Starbucks Tomorrow": People Power Chungbuk Committee and Geoje Mayoral Candidate Face Criticism for Alleged 5·18 Demeaning Remarks
- "Hancom Breaks Away from Its 36-Year Mission and Formula for Success" (Comprehensive)
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
Lee Gi-won, CEO of Ybrain, said, “Through this FDA approval, we have been able to internationally certify the safety and effectiveness of electronic medicine developed with domestic technology.”
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
